Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction

International Journal of Cardiology

Volumn 167, Issue 6, 2013, Pages 2882-2888

  Verschuren, Jeffrey J W ^a   Boden, Helèn ^a   Wessels, Judith A M ^a   Van Der Hoeven, Bas L ^a   Trompet, Stella ^a   Heijmans, Bastiaan T ^a,b   Putter, Hein ^a   Guchelaar, Henk Jan ^a   Schalij, Martin J ^a   Jukema, J Wouter ^a,b,c,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Consortium of Healthy Ageing ^*  (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^d Durrer Center for Cardiogenetic Research   (Netherlands)

Author keywords

Antiplatelet therapy; Cyclooxygenase 1; Cytochrome P450 2C19; Pharmacogenetics; ST segment elevation myocardial infarction; Treatment outcome

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA2 INTEGRIN; ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYCLOOXYGENASE 1; CYTOCHROME P450 2C19; GLYCOPROTEIN IIIA; MULTIDRUG RESISTANCE PROTEIN 1; PURINERGIC P2Y1 RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PRIORITY JOURNAL; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE; TREATMENT OUTCOME;

ANTIPLATELET THERAPY; CYCLOOXYGENASE 1; CYTOCHROME P450 2C19; PHARMACOGENETICS; ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; COHORT STUDIES; CORONARY THROMBOSIS; CYCLOOXYGENASE 1; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHARMACOGENETICS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION SURVEILLANCE; STENTS; TICLOPIDINE;

EID: 84883758234     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.07.020     Document Type: Article

References (39)

1. J.J. Verschuren, S. Trompet, and J.A. Wessels A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J 33 2 2012 165 175
2. J.J. Verschuren, and J.W. Jukema Pharmacogenetics of antiplatelet therapy: ready for clinical application? Heart 97 15 2011 1268 1276
3. J.L. Mega, T. Simon, and J.P. Collet Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 16 2010 1821 1830
4. F. Sofi, B. Giusti, R. Marcucci, A.M. Gori, R. Abbate, and G.F. Gensini Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis Pharmacogenomics J 11 3 2011 199 206
5. M. Zabalza, I. Subirana, and J. Sala Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel Heart 98 2 2012 100 108
6. T. Bauer, H.J. Bouman, J.W. van Werkum, N.F. Ford, J.M. ten Berg, and D. Taubert Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis BMJ 343 2011 d4588
7. M.V. Holmes, P. Perel, T. Shah, A.D. Hingorani, and J.P. Casas CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis JAMA 306 24 2011 2704 2714
8. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 4 2009 363 375
9. K.A. Tiroch, D. Sibbing, and W. Koch Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events Am Heart J 160 3 2010 506 512
10. D. Trenk, W. Hochholzer, and M.F. Fromm Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 20 2008 1925 1934
11. D. Sibbing, J. Stegherr, and W. Latz Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 8 2009 916 922
12. S.S. Liem, B.L. van der Hoeven, and P.V. Oemrawsingh MISSION!: optimization of acute and chronic care for patients with acute myocardial infarction Am Heart J 153 1 2007 14.e1 14.e11
13. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 17 2007 2344 2351
14. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Biol 231 25 1971 232 235
15. M.K. Halushka, L.P. Walker, and P.V. Halushka Genetic variation in cyclooxygenase 1: effects on response to aspirin Clin Pharmacol Ther 73 1 2003 122 130
16. A. Lepantalo, J. Mikkelsson, and J.C. Resendiz Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients Thromb Haemost 95 2 2006 253 259
17. A.O. Maree, R.J. Curtin, and A. Chubb Cyclooxygenase-1 haplotype modulates platelet response to aspirin J Thromb Haemost 3 10 2005 2340 2345
18. T.J. Kunicki, S.A. Williams, and D.J. Nugent Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease Thromb Haemost 101 1 2009 123 133
19. C. Pettinella, M. Romano, L. Stuppia, F. Santilli, R. Liani, and G. Davi Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin Thromb Haemost 101 4 2009 687 690
20. N. Clappers, M.G. van Oijen, and S. Sundaresan The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid Thromb Haemost 100 1 2008 70 75
21. D. Voora, J. Horton, S.H. Shah, L.K. Shaw, and L.K. Newby Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use Am Heart J 162 1 2011 166 172
22. M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D.A. Palisaitis, and J.G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 14 2007 1702 1708
23. T. Goodman, A. Ferro, and P. Sharma Pharmacogenetics of aspirin resistance: a comprehensive systematic review Br J Clin Pharmacol 66 2 2008 222 232
24. B.K. Jefferson, J.H. Foster, and J.J. McCarthy Aspirin resistance and a single gene Am J Cardiol 95 6 2005 805 808
25. Q. Li, B.L. Chen, and V. Ozdemir Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin Pharmacogenomics 8 6 2007 577 586
26. G. Su, Z. Wang, and Y. Ding Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance J Huazhong Univ Sci Technol Med Sci 27 6 2007 664 667
27. H.J. Bouman, E. Schomig, and J.W. van Werkum Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 1 2011 110 116
28. D. Sibbing, W. Koch, and S. Massberg No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting Eur Heart J 32 13 2011 1605 1613
29. D. Trenk, W. Hochholzer, and M.F. Fromm Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement Circ Cardiovasc Genet 4 4 2011 429 436
30. T. Cuisset, P.E. Morange, J. Quilici, J.L. Bonnet, C. Gachet, and M.C. Alessi Paraoxonase-1 and clopidogrel efficacy Nat Med 17 9 2011 1039
31. P. Gladding, M. Webster, and I. Zeng The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial JACC Cardiovasc Interv 1 6 2008 620 627
32. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 11 2011 1097 1105
33. J.L. Mega, W. Hochholzer, and A.L. Frelinger III Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 20 2011 2221 2228
34. G. Parodi, R. Marcucci, and R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 11 2011 1215 1223
35. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 19 2009 2553 2560
36. L. Wallentin, S. James, and R.F. Storey Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 9749 2010 1320 1328
37. W. Wijns, P. Kolh, and N. Danchin Guidelines on myocardial revascularization Eur Heart J 31 20 2010 2501 2555
38. S.A. Scott, K. Sangkuhl, and E.E. Gardner Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy Clin Pharmacol Ther 90 2 2011 328 332
39. H. Schunkert, I.R. Konig, and S. Kathiresan Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease Nat Genet 43 4 2011 333 338